Дифференциальная диагностика инциденталом надпочечников

Инциденталома в широком медицинском понимании является опухолью какого-либо органа, выявленной при радиологическом обследовании случайно (не по поводу болезни данного органа).

1. Young W.F. Jr. Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocr. Metab. Clin. N. Am. 2000; 29:159–185.

2. Bovio S., Cataldi A., Reimondo G. et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocr. Invest. 2006; 29: 298–302.

3. Mansmann G., Lau J., Balk E. et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 2004; 25:309–340.

4. Terzolo M., Pia A., Ali A. et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J. Clin. Endocr. Metab. 2002; 87: 998–1003.

5. Korobkin M., Brodeur F.J., Francis I.R. et al. CT timeattenuation washout curves of adrenal adenomas and nonadenomas. Am. J. Roentgenol. 1998; 170: 747–752.

6. Pena C.S., Boland G.W., Hahn P.F. et al. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrastenhanced CT. Radiology 2000; 217: 798–802.

7. Young W.F.Jr. The Incidentally Discovered Adrenal Mass. N. Engl. J. Med. 2007; 356: 601–610.

8. Barzon L., Sonino N., Fallo F. et al. Prevalence and natural history of adrenal incidentalomas. Eur. J. Endocr. 2003; 149: 273–285.

9. Cawood T.J., Hunt P.J., O’Shea D. et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Literature review. Eur. J. Endocr. 2009; 161: 513–527.

10. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocr. (Oxf.) 1994; 40: 479–484.

11. Lindholm J., Juul S., Jorgensen J.O. et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J. Clin. Endocr. Metab. 2001; 86: 117–123.

12. Pecori G.F., Pivonello R., Ambrogio A.G. et al. The dexamethasonesup ressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. Clin. Endocr. (Oxf.) 2007; 66: 251–257.

13. Ross E.J., Linch D.C. Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646–649.

14. Erbil Y., Ademoglu E., Ozbey N. et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. Wld J. Surg. 2006; 30: 1665–1671.

15. Chiodini I., Tauchmanova L., Torlontano M. et al. Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J. Clin. Endocr. Metab. 2002; 87: 5491–5494.

16. Rossi R., Tauchmanova L., Luciano A. et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocr. Metab. 2000; 85: 1440–1448.

17. Tauchmanova L., Rossi R., Biondi B. et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J. Clin. Endocr. Metab. 2002; 87: 4872–4878.

18. Barzon L., Fallo F., Sonino N., Boscaro M. Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur. J. Endocr. 2002; 146: 61–66.

19. Libe R., Dall’Asta C., Barbetta L. et al. Longterm follow-up study of patients with adrenal incidentalomas. Eur. J. Endocr. 2002; 147: 489–494.

20. Samaras K., Pett S., Gowers A. et al. Iatrogenic Cushing’s syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J. Clin. Endocr. Metab. 2005; 90: 4394–4398.

21. Mann M., Koller E., Murgo A. et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch. Intern. Med. 1997; 157:1651–1656.

22. Nieman L.K., Biller B.M.K., Findling J.W. et al. The diagnosis of Cushing’s syndrome:an endocrine society clinical practice guideline. J. Clin. Endocr. Metab. 2008; 93 (5): 1526–1540.

23. Newell-Price J., Trainer P., Besser M., Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing's states. Endocr. Rev. 1998; 19: 647–672.

24. Crapo L. Cushing’s syndrome: a review of diagnostic tests. Metabolism 1979; 28: 955–977.

25. Cronin C., Igoe D., Duffy M.J. et al. The overnight dexamethasone test is a worthwhile screening procedure. Clin. Endocrinol. (Oxf.) 1990; 33: 27–33.

26. Invitti C., Pecori Giraldi F., de Martin M., Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J. Clin. Endocr. Metab. 1999; 84: 440–448.

27. Findling J.W., Raff H., Aron D.C. The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing’s syndrome. J. Clin. Endocr. Metab. 2004; 89: 1222–1226.

28. Gorges R., Knappe G., Gerl H. et al. Diagnosis of Cushing’s syndrome: re-evaluation of midnight plasma cortisol vs urinary free cortisol and low-dose dexamethasone suppression test in a large patient group. J. Endocr. Invest. 1999; 22: 241–249.

29. Wood P.J., Barth J.H., Freedman D.B. et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome-recommendations or a protocol for biochemistry laboratories. Ann. Clin. Biochem. 1997; 34 (Pt 3): 222–229.

30. Yanovski J.A., Cutler G.B.Jr., Chrousos G.P., Nieman L.K. Corticotropin-releasing hormone stimulation following lowdose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudoCushing’s states. J.A.M.A. 1993; 269: 2232–2238.

31. Eisenhofer G. et al. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr. Pathol. 2003; 14: 193–212.

32. Gardet V. et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J. Hypertens. 2001; 19: 1029–1035;

33. Gerlo E., Sevens C. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin. Chem. 1994; 40: 250–256.

34. Guller U. et al. Detecting pheochromocytoma: defining the most sensitive test. Ann. Surg. 2006. 243: 102–107.

35. Lenders J.W. et al. Biochemical diagnosis of pheochromocytoma: which test is best? J.A.M.A. 2002. 287: 1427–1434.

36. Raber W. et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch. Intern. Med. 2000; 160: 2957–2963.

37. Sawka A.M. et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J. Clin. Endocr. Metab. 2003; 88: 553–558.

38. Unger N. et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur. J. Endocr. 2006; 154: 409–417.

39. Кузнецов Н.С., Бельцевич Д.Г., Гончаров Н.П. и др. Повышение уровня метилированных производных катехоламинов – патогномоничный лабораторный признак феохромоцитомы. Пробл. эндокринол. 2007; 1: 33–36.

40. Erlic Z., Neumann H. Familial pheochromocytoma. Hormones 2009; 1: 29–38.

41. Young W.F.Jr. Primary aldosteronism: management issues. Ann. N. Y. Acad. Sci. 2002; 970: 61–76.

42. Hiramatsu K., Yamada T., Yukimura Y. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Int. Med. 1981;141:1589–1593.

43. Funder J.W. et al. Guidelines for Management of Patients with Primary Aldosteronism. J. Clin. Endocr. Metab. 2008. First published ahead of print June 13.

44. McKenna T.J., Sequeira S.J., Heffernan A. et al. Diagnosis under random conditions of all disorders of the reninangiotensin-aldosterone axis, including primary hyperaldosteronism. J. Clin. Endocr. Metab. 1991; 73: 952–957.

45. Stowasser M., Gordon R.D., Gunasekera T.G. et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J. Hypertens. 2003; 21: 2149–2157.

46. Montori V.M., Schwartz G.L., Chapman A.B. et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin. Proc. 2001. 76: 877–882.

47. Hussain HK, Korobkin M. MR imaging of the adrenal glands. Magn. Reson. Imaging Clin. N. Am. 2004; 12: 515–544.

48. Kempers M., Lenders J. et al. Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism. Ann. Intern. Med. 2009; 151: 329–337.

49. Mansmann G., Lau J., Balk E. et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 2004; 25: 309–340.

50. Young W.F.Jr. The Incidentally Discovered Adrenal Mass. N. Engl. J. Med. 2007; 356: 601–610.